Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nicholas Saccomano | $600,000 | $0 | $0 | $609,934 | $247,500 | $0 | $10,500 | $1,467,934 |
| President and Chief Executive Officer | ||||||||
| Jason Leverone | 444,000 | 0 | 0 | 304,967 | 133,200 | 0 | 14,000 | 896,167 |
| Chief Financial Officer | ||||||||
| Samuel Agresta | 482,000 | 0 | 0 | 211,131 | 144,600 | 0 | 14,000 | 851,731 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nicholas Saccomano | $1,467,934 | $9,515,165 | — | −8,047,231 |
| Jason Leverone | 896,167 | 2,678,570 | — | −1,782,403 |
| Samuel Agresta | 851,731 | 2,841,068 | — | −1,989,337 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Samuel Agresta, M.D. | OPTION | — | — | — | 45,000 | — | $211,131 |
| Jason Leverone, C.P.A. | OPTION | — | — | — | 65,000 | — | 304,967 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Samuel Agresta, M.D. | $0 | $0 | $211,131 | 0.0% |
| Jason Leverone, C.P.A. | 0 | 0 | 304,967 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jason Leverone | RSU | 5,105 | — | $14,805 |
| Saccomano | RSU | 1,424 | — | 4,130 |
| Saccomano | Option | 495 | 13.99 | — |
| Saccomano | Option | 331,364 | 18.2 | — |
| Saccomano | Option | 100,209 | 5.19 | — |
| Jason Leverone | Option | 121 | 21.2 | — |
| Jason Leverone | Option | 1,774 | 13.99 | — |
| Jason Leverone | Option | 79,818 | 18.2 | — |
| Jason Leverone | Option | 50,105 | 5.19 | — |
| Samuel Agresta | Option | 10,069 | 13.99 | — |
| Samuel Agresta | Option | 80,298 | 18.2 | — |
| Samuel Agresta | Option | 34,688 | 5.19 | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew PhillipsIndependent | $87,500 | $0 | $16,294 | — | — | $103,794 |
| Andrew Phillips, Ph.DIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance (Chair) | 87,500 | 0 | 16,294 | — | — | 103,794 |
| Isaac Manke, Ph.DIndependent | 60,497 | 0 | 16,294 | — | — | 76,791 |
| Isaac MankeIndependent | 60,497 | 0 | 16,294 | — | — | 76,791 |
| R. Michael CarruthersIndependent · Audit (Chair) | 55,000 | 0 | 16,294 | — | — | 71,294 |
| Edward MathersIndependent · Audit · Compensation | 44,998 | 0 | 16,294 | — | — | 61,292 |
| Valerie M. Jansen, M.D., Ph.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 16,294 | — | — | 60,294 |
| Michael GreyIndependent | 40,000 | 0 | 16,294 | — | — | 56,294 |
| Dr. SaccomanoEmployee director | — | — | — | — | — | 0 |
| Liam RatcliffeIndependent | 0 | 0 | 0 | — | — | 0 |
| Liam Ratcliffe, Ph.DIndependent · Departed during FY | 0 | 0 | 0 | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 5,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $479,992 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $479,992 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | OnKure Therapeutics, Inc. | 2025 | Nicholas Saccomano | $600,000 | $0 | $609,934 | $247,500 | $1,467,934 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nicholas Saccomano | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 1,467,934. Filing ↗machine: r2 · c18 · span 534923–534932 |
| 2 | Section 01, Jason Leverone | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 896,167. Filing ↗machine: r6 · c18 · span 548645–548652 |
| 3 | Section 01, Samuel Agresta | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation”. As printed: 851,731. Filing ↗machine: r4 · c18 · span 541794–541801 |
| 4 | Section 03, Samuel Agresta, M.D. OPTION | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 483349–483356 |
| 5 | Section 03, Jason Leverone, C.P.A. OPTION | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 480440–480447 |
| 6 | Section 08, Andrew Phillips | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 103,794. Filing ↗machine: span 284670–284849 |
| 7 | Section 08, Andrew Phillips, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 103,794. Filing ↗machine: span 284670–284849 |
| 8 | Section 08, Isaac Manke, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 76,791. Filing ↗machine: span 279858–280076 |
| 9 | Section 08, Isaac Manke | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 76,791. Filing ↗machine: span 279858–280076 |
| 10 | Section 08, R. Michael Carruthers | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 71,294. Filing ↗machine: span 282088–282306 |
| 11 | Section 08, Edward Mathers | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 61,292. Filing ↗machine: span 291665–291883 |
| 12 | Section 08, Valerie M. Jansen, M.D., Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 60,294. Filing ↗machine: span 286870–287088 |
| 13 | Section 08, Michael Grey | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 56,294. Filing ↗machine: span 289442–289660 |
| 14 | Section 08, Dr. Saccomano | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 08, Liam Ratcliffe | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Liam Ratcliffe, Ph.D | DEF 14A | 2026-04-21 | 0001140361-26-015903 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 19 | Section 09b board cost (computed) | Computed | — | computed | Cash 479,992 + equity 0 + all other 0 = 479,992, summed across the director compensation table rows.machine: formula: Σ = 479,992 |
| 20 | OnKure Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001140361-26-015903 | CEO total compensation as printed in OnKure Therapeutics, Inc.'s own proxy. As printed: 1,467,934. Filing ↗machine: r2 · c18 · span 534923–534932 |